POPULATION HEALTH RESOURCES FOR YOU AND YOUR MEMBERS WITH DRUG-INDUCED MOVEMENT DISORDERS

Are you aware of the impact of movement disorders on your members with serious mental illness?



Serious mental illnesses (SMI), such as schizophrenia, bipolar disorder, and major depression, pose a burden to the healthcare system^{1,2}



Drug-induced movement disorders (DIMDs) are part of that burden and may negatively impact a patient's functional capabilities and quality of life^{1,3,4}



Improving the care management of patients with serious mental illness may help improve health outcomes and controlling costs may result in cost savings¹

NEUROCRINE IS COMMITTED TO POPULATION HEALTH AND HELPING WITH THE MANAGEMENT OF PATIENTS WITH MOVEMENT DISORDERS.

In-service Presentation: Drug-Induced Movement Disorders and Tardive Dyskinesia

Would you or your staff like to know more about movement disorders and tardive dyskinesia (TD)?

Neurocrine offers an in-service presentation for case managers, care coordinators, and other staff involved in the care of patients with serious mental illness. This presentation can provide training and education on:

- DIMDs and TD
- Burden of DIMDs
- Recognizing DIMDs
- Population health management considerations



Contact your National Account Executive (NAE) or visit www.Neurocrine4PopHealth.com for information on how you and your team can learn more.





THE FOLLOWING RESOURCES ARE AVAILABLE TO HELP YOU MANAGE YOUR PATIENTS WITH MOVEMENT DISORDERS, PARTICULARLY TD.



Tardive Dyskinesia: A Clinically Distinct, Drug-Induced Movement Disorder

TD disease awareness information, including diagnosis and management considerations.

Audience: HCPs, Case Managers, Formulary Decision-Makers



Identifying Tardive Dyskinesia (TD)

Population management considerations for members with serious mental illness, including factors associated with increased risk for TD, as well as diagnosis and assessment criteria.

Audience: HCPs, Case Managers, Formulary Decision-Makers



Abnormal Movement Ouestionnaire

For use by healthcare professionals to help with the overall assessment of abnormal movements in patients taking antipsychotics for at least 3 months.

Audience: HCPs, Case Managers

TO MEANS HAVING MOVEMENTS YOU CAN'T CONTROL	
Here's a list of quantizers alread anomicalistic means	unia lar yna is amaen.
This quantizeroaire is not a substated assessment tool, nor is it a diagonalic tend to TD TD should be	
diagramati by a matical probabilitati	
 Texas are been estimated in advanced. 	 An analysis of two h. has been been as a second of
Statistic linear to serve a statistical and a statistical server and the serve	U feamenand
	1 Not instanta at all
	8
O Articipation during	0.
O Report America	O ti fumunuli tutturiumu
O titler	
Taxyou apprinted assemblation and	The argume contraction of your resonances'
and according producing biology profile making arrivability in the (second line accord)	Frag which (Scher all Hamapoly.)
	Q ==
0 mm	O function
0	Q franciscular
O spectady	O inter
O Arms	
	S
O Handy Separa	control per anno mentione
O top	
O for	
	#†+
Westernase	STATISTICS AND ADDRESS OF TAXABLE PARTY.
	ADMINISTRATION OF THE OWNER OWNE

Patient Screener: TD Means Having Movements You Can't Control

A list of questions to help with the assessment of abnormal movements in patients taking antipsychotics for at least a few months.

Audience: Patients, Caregivers



Diagnostic Criteria for Tardive Dyskinesia (TD)

Information regarding the diagnosis of TD and the *DSM-5* criteria for definition, symptoms, and duration.

Audience: HCPs, Case Managers, Formulary Decision-Makers



<u>i</u>ii

Assessment of Tardive Dyskinesia (TD): An Overview of the Abnormal Involuntary Movement Scale (AIMS)

Information about assessing patients already diagnosed with TD using the Abnormal Involuntary Movement Scale (AIMS).

Audience: HCPs, Case Managers, Formulary Decision-Makers

RE-KINECT: A Real-World Dyskinesia Screening Study

Highlights of RE-KINECT, a real-world dyskinesia screening study.

Audience: HCPs, Case Managers, Formulary Decision-Makers



Managing Antipsychotic-Associated Movement Disorders for Members With Mental Illness

Highlights recommendations from the 2020 American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Schizophrenia for the management of TD.

Audience: HCPs, Case Managers, Formulary Decision-Makers

For more information or to get access to these resources, please contact your NAE or visit www.Neurocrine4PopHealth.com.

References: 1. Hackbarth NS. https://www.rand.org/content/dam/rand/pubs/working_papers/WR1000/WR1084/RAND_WR1084. pdf. Financing integrated care for adults with serious mental illness in community mental health centers. Accessed August 4, 2020. **2.** Rowan K et al. *Health Aff* (Millwood). 2013;32(10):1723-1730. **3.** Meyers TA et al. *US Pharm*. 2014;39(1):HS13-HS16. **4.** Ascher-Svanum H et al. *J Clin Psych*. 2008;69(10):1580-1588.





POPULATION HEALTH RESOURCES FOR YOU AND YOUR MEMBERS WITH DRUG-INDUCED MOVEMENT DISORDERS

Are you aware of the impact of movement disorders on your members with serious mental illness?



Serious mental illnesses (SMI), such as schizophrenia, bipolar disorder, and major depression, pose a burden to the healthcare system^{1,2}



Drug-induced movement disorders (DIMDs) are part of that burden and may negatively impact a patient's functional capabilities and quality of life^{1,3,4}



Improving the care management of patients with serious mental illness may help improve health outcomes and controlling costs may result in cost savings¹

NEUROCRINE IS COMMITTED TO POPULATION HEALTH AND HELPING WITH THE MANAGEMENT OF PATIENTS WITH MOVEMENT DISORDERS.

In-service Presentation: Drug-Induced Movement Disorders and Tardive Dyskinesia

Would you or your staff like to know more about movement disorders and tardive dyskinesia (TD)?

Neurocrine offers an in-service presentation for case managers, care coordinators, and other staff involved in the care of patients with serious mental illness. This presentation can provide training and education on:

- DIMDs and TD
- Burden of DIMDs
- Recognizing DIMDs
- Population health management considerations



Contact your National Account Executive (NAE) or visit www.Neurocrine4PopHealth.com for information on how you and your team can learn more.





THE FOLLOWING RESOURCES ARE AVAILABLE TO HELP YOU MANAGE YOUR PATIENTS WITH MOVEMENT DISORDERS, PARTICULARLY TD.



Tardive Dyskinesia: A Clinically Distinct, Drug-Induced Movement Disorder

TD disease awareness information, including diagnosis and management considerations.

Audience: HCPs, Case Managers, Formulary Decision-Makers



Identifying Tardive Dyskinesia (TD)

Population management considerations for members with serious mental illness, including factors associated with increased risk for TD, as well as diagnosis and assessment criteria.

Audience: HCPs, Case Managers, Formulary Decision-Makers



Abnormal Movement Ouestionnaire

For use by healthcare professionals to help with the overall assessment of abnormal movements in patients taking antipsychotics for at least 3 months.

Audience: HCPs, Case Managers



Patient Screener: TD Means Having Movements You Can't Control

A list of questions to help with the assessment of abnormal movements in patients taking antipsychotics for at least a few months.

Audience: Patients, Caregivers



Diagnostic Criteria for Tardive Dyskinesia (TD)

Information regarding the diagnosis of TD and the *DSM-5* criteria for definition, symptoms, and duration.

Audience: HCPs, Case Managers, Formulary Decision-Makers



Assessment of Tardive Dyskinesia (TD): An Overview of the Abnormal Involuntary Movement Scale (AIMS)

Information about assessing patients already diagnosed with TD using the Abnormal Involuntary Movement Scale (AIMS).

Audience: HCPs, Case Managers, Formulary Decision-Makers



RE-KINECT: A Real-World Dyskinesia Screening Study

Highlights of RE-KINECT, a real-world dyskinesia screening study.

Audience: HCPs, Case Managers, Formulary Decision-Makers



Managing Antipsychotic-Associated Movement Disorders for Members With Mental Illness

Highlights recommendations from the 2020 American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients with Schizophrenia for the management of TD.

Audience: HCPs, Case Managers, Formulary Decision-Makers

For more information or to get access to these resources, please contact your NAE or visit www.Neurocrine4PopHealth.com.

References: 1. Hackbarth NS. https://www.rand.org/content/dam/rand/pubs/working_papers/WR1000/WR1084/RAND_WR1084. pdf. Financing integrated care for adults with serious mental illness in community mental health centers. Accessed August 4, 2020. **2.** Rowan K et al. *Health Aff* (Millwood). 2013;32(10):1723-1730. **3.** Meyers TA et al. *US Pharm*. 2014;39(1):HS13-HS16. **4.** Ascher-Svanum H et al. *J Clin Psych*. 2008;69(10):1580-1588.



